



PHARMACY PRACTICE AND THE LAW

EIGHTH EDITION

Richard R. Abood, BS Pharm, JD
Professor Emeritus of Pharmacy Practice
Thomas J. Long School of Pharmacy and Health Sciences
University of the Pacific
Stockton, California

Kimberly A. Burns, RPh, JD
Professor of Pharmaceutical Sciences
Lake Erie College of Osteopathic
Medicine (LECOM) School of Pharmacy
Erie, Pennsylvania



JONES & BARTLETT
LEARNING

World Headquarters
Jones & Bartlett Learning
5 Wall Street
Burlington, MA 01803
978-443-5000
info@jblearning.com
www.jblearning.com

Jones & Bartlett Learning books and products are available through most bookstores and online booksellers. To contact Jones & Bartlett Learning directly, call 800-832-0034, fax 978-443-8000, or visit our website, www.jblearning.com.

Substantial discounts on bulk quantities of Jones & Bartlett Learning publications are available to corporations, professional associations, and other qualified organizations. For details and specific discount information, contact the special sales department at Jones & Bartlett Learning via the above contact information or send an email to specialsales@jblearning.com.

Copyright © 2017 by Jones & Bartlett Learning, LLC, an Ascend Learning Company

All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without written permission from the copyright owner.

The content, statements, views, and opinions herein are the sole expression of the respective authors and not that of Jones & Bartlett Learning, LLC. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not constitute or imply its endorsement or recommendation by Jones & Bartlett Learning, LLC and such reference shall not be used for advertising or product endorsement purposes. All trademarks displayed are the trademarks of the parties noted herein. *Pharmacy Practice and the Law, Eighth Edition* is an independent publication and has not been authorized, sponsored, or otherwise approved by the owners of the trademarks or service marks referenced in this product.

There may be images in this book that feature models; these models do not necessarily endorse, represent, or participate in the activities represented in the images. Any screenshots in this product are for educational and instructive purposes only. Any individuals and scenarios featured in the case studies throughout this product may be real or fictitious, but are used for instructional purposes only.

The authors, editor, and publisher have made every effort to provide accurate information. However, they are not responsible for errors, omissions, or for any outcomes related to the use of the contents of this book and take no responsibility for the use of the products and procedures described. Treatments and side effects described in this book may not be applicable to all people; likewise, some people may require a dose or experience a side effect that is not described herein. Drugs and medical devices are discussed that may have limited availability controlled by the Food and Drug Administration (FDA) for use only in a research study or clinical trial. Research, clinical practice, and government regulations often change the accepted standard in this field. When consideration is being given to use of any drug in the clinical setting, the health care provider or reader is responsible for determining FDA status of the drug, reading the package insert, and reviewing prescribing information for the most up-to-date recommendations on dose, precautions, and contraindications, and determining the appropriate usage for the product. This is especially important in the case of drugs that are new or seldom used.

09716-0

Production Credits

VP, Executive Publisher: David D. Cella
Publisher: Cathy L. Esperti
Associate Director of Production: Julie C. Bolduc
Editorial Assistant: Sara J. Peterson
Associate Production Editor: Alex Schab
Marketing Manager: Grace Richards
Rights & Media Research Assistant: Merideth Tumasz
Rights & Media Research Coordinator: Mary Flatley
Media Development Editor: Shannon Sheehan
VP, Manufacturing and Inventory Control: Therese Connell

Composition: Cenveo® Publisher Services
Cover Design: Scott Moden
Cover Image: © RoyStudio.eu/Shutterstock
Take-Away Points Image: © AnthiaCumming/Getty Images
Study Scenarios Image: © Stockbyte/Thinkstock
Case Studies Image: © Junial Enterprises/Shutterstock
Printing and Binding: Edwards Brothers Malloy
Cover Printing: Edwards Brothers Malloy

Library of Congress Cataloging-in-Publication Data

Abood, Richard R., author.

Pharmacy practice and the law/Richard R. Abood, Kimberly A. Burns. —Eighth edition.

pages cm

ISBN 978-1-284-08911-0

1. Pharmacists—Legal status, laws, etc.—United States. 2. Pharmacy—Law and legislation—United States.

3. Drugs—Law and legislation—United States. I. Burns, Kimberly A., author. II. Title.

KF2915.P4A93 2016

344.7304'16—dc23

2015026503

6048

Printed in the United States of America
19 18 17 16 15 10 9 8 7 6 5 4 3 2 1



To Jeri, Aaron, and Meredith
RRA

To Pete, Cassidy, and Karalynn
KAB



BRIEF CONTENTS

Table of Cases	xix	
Preface	xxiii	
New to the <i>Eighth Edition</i>	xxv	
A Special Acknowledgment	xxix	
Reviewers	xxx	
Chapter 1	The Law and the Legal System	1
Chapter 2	Federal Regulation of Medications: Development, Production, and Marketing	41
Chapter 3	Federal Regulation of Medications: Dispensing	137
Chapter 4	The Closed System of Controlled Substance Distribution	203
Chapter 5	Dispensing Controlled Substances	247
Chapter 6	Federal Regulation of Pharmacy Practice	305
Chapter 7	State Regulation of Pharmacy Practice	379
Chapter 8	Pharmacist Malpractice Liability and Risk Management Strategies	425
Glossary	487	
Index	493	

CONTENTS

Table of Cases	xix	
Preface	xxiii	
New to the <i>Eighth Edition</i>	xxv	
A Special Acknowledgment	xxix	
Reviewers	xxx	
Chapter 1	The Law and the Legal System	1
	The Nature and Role of Law	2
	<i>Reasons to Regulate Medicinal Drugs</i>	3
	<i>Limits of the Law</i>	5
	Take-Away Points	6
	Study Scenarios and Questions	6
	Sources of U.S. Law	6
	<i>The Constitution of the United States</i>	7
	<i>Law Made by Legislatures: Statutory Law</i>	7
	<i>Law Made by Administrative Agencies</i>	7
	<i>Law Made by the Courts: Common Law</i>	10
	<i>Distinguishing Criminal, Civil, and Administrative Law</i>	12
	Take-Away Points	13
	Study Scenarios and Questions	13
	The Legislative Process	14
	<i>Federal Level</i>	14
	<i>State Level</i>	15
	Take-Away Points	16
	The Judicial Process	16
	<i>The Federal Court System</i>	16
	<i>The State Court System</i>	17
	<i>Civil Court Procedures</i>	18
	<i>Criminal Court Procedures</i>	22
	<i>Case Citation and Analysis</i>	23
	Take-Away Points	23
	Study Scenarios and Questions	24
	Federal Versus State Law	24
	<i>Federal Authority to Regulate</i>	24
	<i>State Authority to Regulate</i>	25
	Take-Away Points	25
	Study Scenarios and Questions	26
	Case Studies	26

Chapter 2	Federal Regulation of Medications: Development, Production, and Marketing	41
	Historical Overview of the Federal Food, Drug, and Cosmetic Act	42
	<i>Pure Food and Drug Act of 1906</i>	42
	<i>Food, Drug, and Cosmetic Act of 1938</i>	43
	<i>Durham-Humphrey Amendment of 1951</i>	44
	<i>Food Additives Amendment of 1958</i>	44
	<i>Color Additive Amendments of 1960</i>	44
	<i>Kefauver-Harris Amendment of 1962</i>	44
	<i>Medical Device Amendments of 1976</i>	45
	<i>Orphan Drug Act of 1983</i>	45
	<i>Drug Price Competition and Patent Term Restoration Act of 1984</i>	45
	<i>Prescription Drug Marketing Act of 1987</i>	45
	<i>Safe Medical Devices Act of 1990</i>	46
	<i>The Generic Drug Enforcement Act of 1992</i>	46
	<i>Prescription Drug User Fee Act of 1992 (PDUFA)</i>	46
	<i>Nutrition Labeling and Education Act of 1990 (NLEA)</i>	46
	<i>Dietary Supplement Health and Education Act of 1994 (DSHEA)</i>	46
	<i>Food and Drug Administration Modernization Act of 1997 (FDAMA)</i>	46
	<i>Food and Drug Administration Amendments Act of 2007 (FDAAA)</i>	47
	<i>Patient Protection and Affordable Care Act of 2010 (PPACA/ACA)</i>	47
	<i>FDA Safety and Innovation Act of 2012 (FDASIA)</i>	47
	<i>Drug Quality and Security Act of 2013 (DQSA)</i>	48
	<i>Rationale for Federal Drug Regulation</i>	48
	Take-Away Points	49
	The Food and Drug Administration (FDA)	49
	Take-Away Points	50
	Defining and Distinguishing Drugs from Foods, Dietary Supplements, Devices, and Cosmetics	51
	<i>The Law</i>	51
	<i>Explanation of the Law</i>	51
	<i>Foods Versus Drugs</i>	53
	<i>Dietary Supplements Versus Drugs</i>	56
	<i>Drugs Versus Devices</i>	61
	<i>Drugs Versus Cosmetics</i>	61
	<i>Labels and Labeling</i>	62
	<i>Official Compendia</i>	62
	Take-Away Points	63
	Study Scenarios and Questions	64
	Prohibited Acts, Penalties, and Enforcement	64
	<i>Prohibited Acts: The Law</i>	64
	<i>Explanation of the Law</i>	65
	<i>Enforcement</i>	66
	<i>Corporate Officer Liability</i>	66
	<i>Product Recalls</i>	67
	Take-Away Points	67
	Adulteration	68

<i>Adulteration: The Law</i>	68
<i>Explanation of Adulteration</i>	68
<i>Current Good Manufacturing Practice (CGMP)</i>	69
<i>Product Tampering</i>	69
Take-Away Points	70
Misbranding	70
<i>Misbranding: The Law</i>	70
<i>Explanation of Misbranding</i>	72
<i>Nonprescription Drug Labeling</i>	74
<i>Prescription Drug Labels and Labeling</i>	77
<i>National Drug Code Number</i>	80
Take-Away Points	81
Study Scenarios and Questions	82
New Drug Approval	82
<i>Defining “New Drug”</i>	83
<i>Approved Drugs as New Drugs</i>	83
<i>The Road to an Approved New Drug Application</i>	84
<i>Drug Efficacy Study Implementation</i>	89
<i>“Paper” New Drug Applications</i>	90
<i>Drug Price Competition and Patent Term Restoration Act (PTRA) of 1984</i>	91
<i>Over-the-Counter Drug Review</i>	95
Take-Away Points	96
Marketed Unapproved Drugs	97
Take-Away Points	98
Drugs Intended to Treat Serious and Life-Threatening Diseases	98
<i>Widespread Patient Treatment with Investigational Drugs (§ 561)</i>	99
<i>Individual Patient Access to Investigational Drugs for Serious Diseases (Parallel Track Policy) (§ 561)</i>	99
Expedited Approval of Drugs Intended to Treat Serious or Life-Threatening Illnesses (“Fast Track Approval”) (§ 506)	100
Take-Away Points	101
Biologics	101
Take-Away Points	103
MedWatch Voluntary Reporting Program	103
<i>Pharmacy Requirement to Provide Patients with MedWatch Number</i>	103
Take-Away Points	104
Medical Devices	104
Take-Away Points	106
Cosmetics	106
Take-Away Points	107
Study Scenarios and Questions	107
Drug Advertising and Promotion	108

	<i>The First Amendment to the U.S. Constitution</i>	108
	<i>Prescription Drug Advertising: Manufacturer to Professionals</i>	109
	<i>Prescription Drug Advertising: Manufacturer to Consumer</i>	113
	<i>Promoting Prescription Drugs and Devices Through Social Media</i>	115
	<i>Promoting Prescription Drugs and Devices for Off-Label Uses</i>	115
	<i>Nonprescription Drug Advertising by Manufacturers</i>	117
	<i>The Lanham Trademark Act</i>	118
	Take-Away Points	119
	Study Scenarios and Questions	120
	Case Studies	121
Chapter 3	Federal Regulation of Medications: Dispensing	137
	The Durham-Humphrey Amendment of 1951	138
	<i>The Law</i>	138
	<i>Explanation of the Durham-Humphrey Amendment</i>	139
	<i>Switch of Prescription Drugs to Over-the-Counter Drugs</i>	143
	<i>Professional Practice Considerations</i>	145
	Take-Away Points	150
	Study Scenarios and Questions	150
	Prescription Drug Labeling Information for the Patient	151
	<i>Patient Package Inserts</i>	151
	<i>Useful Written Patient Information and Medication Guides</i>	152
	<i>Drug Information Website for Pharmacists: Drug Info Rounds</i>	155
	<i>Drug Information Website for Consumers and Health Professionals: Drugs@FDA</i>	155
	Take-Away Points	155
	Study Scenario and Question	155
	Approved Drugs for Off-Label (Unlabeled) Indications	156
	Take-Away Points	157
	Study Scenarios and Questions	157
	Pharmacy Compounding Versus Manufacturing	158
	<i>FDA 1992 Compliance Policy Guide</i>	159
	<i>FDAMA's Compounding Provisions (§ 503A)</i>	159
	<i>FDA 2002 Compliance Policy Guide (CPG)</i>	160
	<i>New Drug Issue</i>	161
	<i>Drug Quality and Security Act of 2013</i>	161
	<i>Draft Compliance Guides</i>	163
	<i>Other Compounding Issues</i>	163
	<i>USP Compounding Requirements</i>	163
	<i>Patent Issues</i>	164
	Take-Away Points	164
	Study Scenarios and Questions	165
	The Orange Book and Generic Substitution	165
	<i>State Generic Substitution Laws</i>	165
	<i>Importance of the Orange Book in Generic Substitution</i>	166

	Narrow Therapeutic Index (NTI) Drugs	169
	Take-Away Points	169
	Study Scenarios and Questions	170
	Prescription Drug Marketing Act of 1987	170
	<i>Regulation of Prescription Drug Samples</i>	170
	<i>Purchases and Resales by Hospitals and Healthcare Entities</i>	171
	<i>Product Returns</i>	172
	<i>Wholesale Distributors</i>	172
	<i>Pedigrees, Counterfeit Drugs, and Drug Supply Chain Security</i>	172
	<i>Importation of Prescription Drugs for Personal Use</i>	175
	<i>Penalties</i>	177
	Take-Away Points	177
	Study Scenarios and Questions	177
	Inspections Under the Federal Food, Drug, and Cosmetic Act	178
	Take-Away Points	178
	Related Laws to the FDCA	178
	<i>Use of Alcohol in Pharmacy Practice</i>	178
	<i>Poison Prevention Packaging Act</i>	179
	Take-Away Points	181
	Study Scenarios and Questions	182
	Drug Advertising by Pharmacies	182
	<i>Price Advertising</i>	182
	<i>Product Advertising: Strict Liability</i>	182
	<i>State Advertising Laws: The Virginia Case and the First Amendment</i>	183
	Take-Away Points	185
	Study Scenario and Question	185
	Case Studies	186
Chapter 4	The Closed System of Controlled Substance Distribution	203
	State Versus Federal Authority	204
	Take-Away Points	205
	Classification of Controlled Substances	206
	<i>Schedule I (Drugs and Other Substances)</i>	206
	<i>Schedule II (Drugs and Other Substances)</i>	208
	<i>Schedule III (Drugs and Other Substances)</i>	208
	<i>Schedule IV (Drugs and Other Substances)</i>	209
	<i>Schedule V (Drugs and Other Substances)</i>	209
	Take-Away Points	209
	Authority for Scheduling	210
	Take-Away Points	210

Manufacturer Labeling and Packaging	210
Take-Away Points	211
Registration	211
Exemptions	211
Activities That Require Registration	213
Applications for Registration and Reregistration	217
Modification, Transfer, and Termination of Registration	217
Denial, Revocation, or Suspension of Registration	218
Take-Away Points	219
Security Requirements	219
Take-Away Points	220
Penalties	220
Drug Trafficking Offenses	221
Distributing or Dispensing in Violation of the Controlled Substances Act	221
Order Form 222 Violation	221
Illegal Possession	221
State Board Discipline	222
Take-Away Points	222
Study Scenarios and Questions	222
Pharmacy Inspections	223
Constitutional Requirements	223
DEA Inspections Under the CSA	223
State Pharmacy Board Inspections	227
Practical Considerations	228
Take-Away Points	228
Study Scenario and Questions	228
Opioid Treatment Programs	229
Methadone	230
Treatment of Addicts Outside of OTPs (DATA)	231
Take-Away Points	232
Study Scenario and Questions	232
Laws Related to the Controlled Substances Act	232
The Controlled Substance Registrant Protection Act of 1984	232
The Chemical Diversion and Trafficking Act of 1988	233
The Anabolic Steroids Act of 2004	233
The Combat Methamphetamine Epidemic Act (CMEA) of 2005 and the Methamphetamine Prevention Act of 2008	234
U.S. Postal Laws: Mailing Controlled Substances	235
Take-Away Points	236
Study Scenario and Questions	236
Case Studies	237

Chapter 5	Dispensing Controlled Substances	247
	Prescriptions	248
	<i>Those Allowed to Prescribe Controlled Substances</i>	248
	<i>Those Allowed to Dispense Controlled Substances</i>	250
	<i>Issuance of Prescriptions</i>	250
	<i>Purpose of a Controlled Substance Prescription</i>	252
	<i>Dispensing of Schedule II Controlled Substances</i>	258
	<i>Dispensing of Schedule III, IV, and V Controlled Substances</i>	262
	<i>Electronic Transmission Prescriptions</i>	265
	<i>Transferring of Prescription Information</i>	266
	<i>Return of Controlled Substances to Pharmacy for Disposal</i>	267
	<i>Central Filling of Prescriptions</i>	268
	<i>Internet Pharmacy Prescriptions</i>	269
	<i>State Electronic Prescription Monitoring Programs</i>	270
	<i>Long-Term Care (LTC) Pharmacy</i>	271
	Take-Away Points	273
	Study Scenarios and Questions	274
	Recordkeeping	275
	<i>The Importance of Adequate Recordkeeping</i>	276
	<i>General Recordkeeping Requirements</i>	276
	<i>Inventory Records</i>	277
	<i>Records of Receipt</i>	278
	<i>Records of Dispersal</i>	278
	<i>Records Required of Individual Practitioners</i>	282
	Take-Away Points	282
	Drug Enforcement Administration Order Form 222	283
	<i>Execution of Order Form 222</i>	283
	<i>Proposed Single Copy Form 222</i>	285
	<i>Electronic DEA Order System (CSOS)</i>	285
	<i>Power of Attorney</i>	286
	<i>Distributions of Schedule I and II Drugs Between Registrants</i>	287
	<i>Lost or Stolen Order Forms</i>	287
	<i>Preservation of Forms</i>	287
	Take-Away Points	288
	Study Scenarios and Questions	288
	Case Studies	289
Chapter 6	Federal Regulation of Pharmacy Practice	305
	The Omnibus Budget Reconciliation Act of 1990	306
	<i>Background</i>	307
	<i>Basic Framework of OBRA '90</i>	307
	<i>Components of Prospective Drug Use Review</i>	310
	Take-Away Points	313
	Study Scenario and Questions	313
	Health Insurance Portability and Accountability Act of 1996	313
	<i>Examples of Privacy Abuses</i>	314

<i>Who Must Comply with HIPAA</i>	315
<i>Protected Health Information</i>	315
<i>Notice Provision</i>	315
<i>Acknowledgment of Notice</i>	316
<i>Use and Disclosure of PHI</i>	316
<i>Business Associates</i>	321
<i>Training Programs</i>	322
<i>Policies and Procedures</i>	322
<i>Penalties and Enforcement</i>	322
<i>Health Information Technology Infrastructure</i>	323
Take-Away Points	323
Study Scenario and Questions	324
Medicare	324
<i>Medicare Part D</i>	325
<i>Medicare and Provider Status for Pharmacists</i>	331
<i>Medicare and the Regulation of Hospital Pharmacy</i>	331
Take-Away Points	333
Medicaid	334
<i>Prescription Drug Coverage</i>	335
Take-Away Points	340
Medicare/Medicaid Fraud and Abuse Laws	341
<i>False Claims Act (FCA)</i>	341
<i>Anti-Kickback Statute (AKS)</i>	342
<i>Physician Anti-Self-Referral Law (The Stark Law)</i>	344
Take-Away Points	345
Study Scenarios and Questions	345
Federal Regulation of Long-Term Care	346
<i>The Trend Toward Long-Term Care</i>	346
<i>Self-Administration of Drugs</i>	346
<i>Unnecessary Drugs</i>	347
<i>Fourteen-Day Dispensing Cycle</i>	347
<i>Medication Errors</i>	348
<i>Pharmacy Services</i>	348
<i>Service Consultation</i>	348
<i>Drug Regimen Review (Consultant Pharmacist)</i>	349
<i>Labeling of Drugs and Biologicals</i>	349
<i>Storage of Drugs and Biologicals</i>	349
Take-Away Points	350
Federal Antitrust Laws	350
<i>The Sherman Antitrust Act</i>	350
<i>The Robinson-Patman Act</i>	357
Take-Away Points	361
Study Scenarios and Questions	362
Miscellaneous Federal Laws Related to Pharmacy Practice	363

	340B Drugs	363
	The Patient Safety and Quality Improvement Act of 2005	364
	Flexible Spending and Health Savings Account Debit Cards	365
	Take-Away Points	365
	Case Studies	366
Chapter 7	State Regulation of Pharmacy Practice	379
	Self-Regulation in Pharmacy	380
	Take-Away Points	380
	Approaches to Regulation	381
	Reasons to Regulate Professions	381
	Differing Perspectives on Regulation	381
	Take-Away Points	382
	State Boards of Pharmacy	382
	Take-Away Points	383
	Licensing	383
	Licensing of Pharmacists	383
	Licensing of Pharmacies	385
	Take-Away Points	387
	Actions Against a License	387
	Grounds for Discipline	388
	Reinstatement of a Revoked License	390
	Impaired Pharmacist Programs	391
	Take-Away Points	391
	Actions Against a Pharmacy License	391
	Take-Away Points	392
	Standards of Practice	392
	Practice of Pharmacy Defined	393
	Ancillary Pharmacy Personnel	394
	Interns	395
	Automation	395
	Absence of a Pharmacist	396
	Continuing Education	396
	Collaborative Practice Agreements	396
	Prospective Drug Utilization Review	397
	Take-Away Points	397
	Repository or Take-Back Programs	398
	Take-Away Points	398
	State Hospital Pharmacy Licensure Issues	398
	Take-Away Points	399
	State Regulation of Long-Term Care	399

	Take-Away Points	400
	State Regulation of Third-Party Plans	401
	<i>State Legislative Efforts to Regulate</i>	
	<i>Third-Party Plans</i>	401
	<i>Regulation of Managed Care Plan Formularies</i>	403
	Take-Away Points	403
	Regulation for Outcomes	404
	<i>Structure, Process, and Outcomes</i>	404
	<i>An Alternative Approach to Regulation</i>	404
	<i>Continuous Quality Improvement Programs</i>	405
	Take-Away Points	406
	Study Scenarios and Questions	406
	Case Studies	407
Chapter 8	Pharmacist Malpractice Liability and Risk Management Strategies	425
	Legal Procedure	426
	Take-Away Points	427
	The Malpractice Action	427
	<i>Elements of Negligence</i>	427
	<i>Defenses to Negligence</i>	434
	<i>Vicarious Liability</i>	436
	Take-Away Points	436
	Study Scenarios and Questions	437
	Liability for Failure to Perform Expanded Responsibilities	438
	<i>Expanded Responsibilities in Perspective</i>	439
	<i>An Expanded View of Pharmacist Duty</i>	440
	<i>Rationale for Expanded Pharmacist Duties</i>	443
	<i>Expanded Responsibilities: A Judicial Compromise</i>	446
	Take-Away Points	446
	Study Scenarios and Questions	446
	Risk Management Strategies	447
	<i>Institutional Controls: Corporate Negligence</i>	448
	<i>Continuous Quality Improvement (CQI) Programs as Risk Management</i>	451
	Take-Away Points	452
	The Pharmacist as Risk Manager	452
	<i>Problems and Pitfalls of Risk Management</i>	452
	<i>Rules for Effective Risk Management</i>	453
	Take-Away Points	455
	Malpractice Insurance	455
	Take-Away Points	455

Study Scenarios and Questions	456
Drug Product Liability	457
<i>Drug Product Defect</i>	457
<i>Grounds for Liability Actions</i>	458
<i>Duty to Warn Under Strict Liability</i>	458
<i>Duty to Warn Under the Learned Intermediary Doctrine</i>	460
<i>Whether FDA-Approved Labeling Preempts State Product Liability Actions</i>	461
<i>Pharmacists and Product Liability</i>	462
Take-Away Points	465
Study Scenarios and Questions	466
Case Studies	467
Glossary	487
Index	493



TABLE OF CASES

A

Abbott Laboratories v. Portland Retail Druggists Association, Inc., 358
Abigail Alliance for Better Access to Developmental Drugs and Washington Legal Foundation v. Eschenbach, 99
Action on Smoking and Health v. Harris, 52
Agbogun v. State, 166
Alberty Food Products Co. v. United States, 73
American Home Products Corporation v. Johnson & Johnson, 118
American Pharmaceutical Association v. Weinberger, 230, 366–369
AnazaoHealth Corporation v. Holder, 216
Arizona v. Maricopa County Medical Society, 356
Aucoin v. Vicknair, 436

B

Baker v. Arbor Drugs, Inc., 444–445
Bates v. State Bar of Arizona, 184
Batiste v. American Home Products, 463
Beaty v. Food and Drug Administration, 40
Bichler v. Willing, 463
Blais v. Rhode Island Department of Health, 5
Blue Cross and Blue Shield v. Peacock's Apothecary, Inc., 402
BMW of North America, Inc. v. Gore, 198
Board of Pharmacy v. Snyder's Drug Stores, 385
Bond v. Walker Pharmacy, 18–22
B.R. ex rel. Jeffs v. West, 429
Bristol-Myers Squibb Co. v. Shalala, 94
Brown v. Superior Court, 458–459
Burke v. Bean, 434
Burroughs Wellcome Co. v. Schweiker, 91

C

Cackowski v. Wal-Mart Stores, Inc., 473–476
Cafazzo v. Central Medical Health Services, Inc., 463
Camara v. Municipal Court, 226
Cazes v. Raisinger, 431–432
Centocor, Inc. v. Hamilton et al., 461
Central Hudson Gas v. Public Service Commission, 109, 134–135
Ciba Corporation v. Weinberger, 89
Cohen v. Missouri Board of Pharmacy, 30–34
Colonnade Catering v. United States, 227
Conant v. Walters, 207
Crain v. Eckerd Corp., 436
Cruzan v. Director, Missouri Department of Health, 99
Cutler v. Kennedy, 96
CVS Pharmacy v. Wayne, 184

D

Daniel Family Pharmacy, 263, 297–301
De Modena v. Kaiser Foundation Health Plan, Inc., 360
DeCordova v. State of Colorado, 428
Docken v. Ciba-Geigy, 428
Douglas v. Independent Living Center of Southern California, Inc., 339
Drug Mart Pharmacy Corp. v. American Home Products, 361

E

Eastern Railroad Presidents Conference v. Noerr Motor Freight, 357

Empire State Pharmaceutical Society v. New York State Department of Education, 388

F

Federal Trade Commission v. Actavis, Inc., 93
 Ferrara v. Berlex Laboratories, Inc., 460
 Fink v. State Board of Pharmacy, 400
 Fleet and Semple v. Hollenkemp, 463
 Food and Drug Admin. v. Brown & Williamson Tobacco Corp., 52–53

G

General Motors Corporation v. Caldwell, 402
 Gonzales v. Raich, 205
 Gordon v. Frost, 254, 295–297
 Griffin v. Phar-Mor, Inc., 443–444
 Griffiths v. Superior Court (Medical Bd. of California), 390
 Group Life and Health Insurance Co. v. Royal Drug Co., 353

H

Hanlester Network v. Shalala, 342
 Happel v. Wal-Mart Stores, Inc., 444, 446, 467–470
 Harco Drugs, Inc. v. Holloway, 448–451
 Harder v. F. C. Clinton, Inc., 375–378
 Hayes v. Travelers Insurance Co., 432
 Heckler v. Chaney, 37–40
 Hinchy v. Walgreen Co., et al., 323
 Hoffman LaRoche, Inc. v. Weinberger, 90
 Hooks SuperX, Inc. v. McLaughlin, 440–443
 Horner v. Spalitto, 369–372
 Houck v. Iowa Bd. of Pharmacy Examiners, 163
 Huggins v. Longs Drug Stores, Inc., 429
 Hundley v. Rite Aid, 451, 470–473

I

In re 882 East 108th Street Drug Corp., 392
 In re Brand Name Prescription Drugs Antitrust Litigation, 361
 In re Heller, 389
 In re Pharmaceutical Industry Average Wholesale Price Litigation, 338
 In the Matter of the Application of W.D.P., 384
 In the Matter of CVS Pharmacy Wayne, 184, 411–414
 In the Matter of Sobel v. Board of Pharmacy, 384, 411–414

Independent Living Center of Southern California v. Maxwell-Jolly, 339
 Independent Living Center of Southern California v. Shewry, 339
 Ingram v. Hook's Drug, 439
 Izzo v. Manhattan Medical Group, 431

J

Jefferson County Pharmaceutical Association, Inc. v. Abbott Laboratories, 360
 Jones v. Alabama State Board of Pharmacy, 390

K

Kampe v. Howard Stark Professional Pharmacy, Inc., 369
 Kennedy v. Kentucky Board of Pharmacy, 199–201
 Kentucky Ass'n of Health Plans, Inc. v. Miller, 403
 Key Enterprises of Delaware, Inc. v. Venice Hospital, 355
 Klamath-Lake Pharmaceutical Association v. Klamath Medical Service Bureau, 350
 Klasch v. Walgreen Co., 470

L

Lasley v. Shrake's Country Club Pharmacy, Inc., 470
 Leesley v. West, 465
 Lemmon Company v. State Board of Medical Examiners, 204, 240–243
 Lou v. Smith, 430
 Louisiana v. U.S. Department of Health and Human Services, 338
 Love v. Escambia County, 385

M

Magan Medical Clinic v. Board of Medical Examiners, 385
 Magrine v. Krasnica, 463
 Makripodis v. Merrell-Dow Pharmaceuticals, 464
 Malan v. Huesemann, 34–37
 Managed Pharmacy Care v. Sebelius, 339
 Marshall v. Barlow's, Inc., 227
 Massachusetts Pharmaceutical Association v. Rate Setting Commission, 340
 McKee v. American Home Products, Inc., 440
 McLeod v. W. S. Merrell Co., 463
 Medical Arts Pharmacy of Stanford, Inc. v. Blue Cross and Blue Shield of Connecticut, Inc., 354

Medical Center Pharmacy v. Gonzales, 161
 Medical Center Pharmacy v. Mukasey, 161
 Menzel v. Morse, 374
 Mississippi State Board of Pharmacy v. Steele, 183
 Missouri Hospital Association v. Missouri
 Department of Consumer Affairs, 398
 Morgan v. Wal-Mart Stores, Inc., 446
 Morlino v. Medical Center of Ocean County, 192
 Morr-Fitz, Inc. v. Quinn, 149
 Mulder v. Parke-Davis & Co., 157, 192
 Murphy v. E. R. Squibb and Sons, Inc., 464

N

NACDS & NCPA v. U.S. DHHS et al., 336
 National Association of Chain Drug Stores v. New
 England Carpenters Health Benefits Fund, 338
 National Federation of Independent Business v.
 Sebelius, 47
 National Nutritional Foods Association v.
 Mathews, 53
 Nelms v. Walgreen Co., 476–480
 New England Carpenters Health Benefits Fund v.
 First DataBank, Inc., 338
 Noesen v. State, Dept. of Regulation
 and Licensing, 148
 North Carolina Board of Pharmacy v. Rules
 Review Commission, 9
 Northern California Pharmaceutical Association v.
 United States, 352
 Northwest Wholesale Stationers, Inc. v. Pacific
 Stationery and Printing Co., 357
 Nutraceutical Corp. v. Crawford, 59
 Nutraceutical Corp. v. Von Eschenbach, 59
 Nutrilab, Inc., et al. v. Schweiker, 53, 121–124
 NVE, Inc. v. Department of Health and Human
 Services, 59

O

Odell v. Axelrod, 400
 Ouellette v. Mills, 176

P

Parker v. Yen, 430
 Patterson Drug Co. v. Kingery, 183
 Pearson v. Shalala, 57
 Pennsylvania Pharmaceutical Association v.
 Department of Public Welfare, 339
 Pennsylvania State Board of Pharmacy
 v. Cohen, 389

People v. Stuart, 26–30
 Perez v. Wyeth Laboratories, Inc., 114, 461
 Pfizer, Inc. v. Shalala, 167–169, 193–196
 Pharmaceutical Manufacturers Association v. Food
 and Drug Administration, 141, 151, 186–190
 Pharmaceutical Research and Manufacturers of
 America v. U.S. Dept. of HHS, 364
 Pharmanex, Inc. v. Shalala, 58
 Pike v. Bruce Church, 386
 Pittman v. The Upjohn Co., 443
 Pliva, Inc. et al. v. Mensing, 94, 462
 Porter & Dietsch, Inc. v. Federal Trade
 Commission, 117, 182–183
 Powers v. Thobhani, 444
 Premo Pharmaceutical Laboratories, Inc. v. United
 States, 90

R

Ramon v. Farr, 157, 190–193
 Riegel v. Medtronic, 462
 Riff v. Morgan Pharmacy, 438
 Rite Aid Corp. v. Board of Pharmacy, 383
 Rite Aid of New Jersey, Inc. v. Board
 of Pharmacy, 9
 Royal Drug Co. v. Group Life and Health
 Insurance Co., 353, 402
 RxUSA Wholesale, Inc., et al. v. DHHS, 173
 Ryan v. Dan's Food Stores, Inc., 254, 292–295

S

Sanchez ex rel, Sanchez v. Wal-Mart, 429
 Sausalito Pharmacy, Inc. v. Blue Shield of
 California, 354
 Schaubman v. Blum, 390
 Schiffman v. Department of Professional
 Regulation, 390
 Schlieter v. Carlos, 152
 Schram v. Department of Professional Regulation,
 388, 420–423
 Schwartz v. Florida Board of Pharmacy, 389
 See v. City of Seattle, 226
 Sender v. Department of Professional
 Regulation, 391
 Shaw v. Delta Airlines, 402
 Sheffield v. State Education Department, 399
 Skilstaf, Inc. v. CVS Caremark Corp, 338
 Sloman v. Iowa Board of Pharmacy Examiners, 291
 Sobel v. Board of Pharmacy, 384, 414–417
 Sorrell v. IMS Health Inc., 133
 Sottera, Inc. v. Food and Drug Administration, 53

Speer v. United States, 432
 Springhill Hospitals, Inc. v. Larrimore, 470
 State v. Brown, 390
 State of Vermont v. Leavitt, 176
 State of Vermont v. Welch, 227
 State v. Rasmussen, 204, 237–240
 Stone et al. v. City of Stow et al., 227
 Stormans, Inc. v. Selecky, 149
 Sullivan v. Sisters of St. Francis of Texas, 332
 Supermarkets General Corporation v. Sills, 183

T

Thompson v. Western States Medical Center, 160
 Troppi v. Scarf, 426
 Tummino v. Hamburg, 148
 Tummino v. Torti, 147

U

United Mine Workers v. Pennington, 357
 United States v. An Article . . . Consisting of 216
 Cartoned Bottles, More or Less, “Sudden
 Change,” 61
 United States v. An Article of Drugs . . . 47 Shipping
 Cartons, More or Less . . . “Helene Curtis
 Magic Secret,” 61–62
 United States v. Article of Drug Bacto Unidisk, 61
 United States v. Article of Drug Ova II, 61
 United States v. Article of Drug—Decholin, 140
 United States v. Articles of Drug (Midwest
 Pharmaceuticals), 73
 United States v. Articles of Drug . . . Lannett Co., 90
 United States v. Baxter Healthcare Corporation,
 83, 333
 United States v. Biswell, 227
 United States v. Bycer, 276
 United States v. Caronia, 116, 132–136
 United States v. Collier, 290–291
 United States v. Dotterweich, 66
 United States v. Enserro, 225
 United States v. Evers, 157
 United States v. Franck’s Lab, Inc., 161
 United States v. Generix Drug Corporation, 90
 United States v. Greber, 342
 United States v. Guardian Chemical Corporation,
 23, 62
 United States v. Hayes, 252–253, 289–291
 United States v. Hiland, 65, 124–129
 United States v. Johnson, 43
 United States v. Krizek, 341
 United States v. Lawson, 253
 United States v. Little, 221, 243–246

United States v. Lopez, 205
 United States v. McClatchey, 342
 United States v. Moore, 254, 290
 United States v. Oakland Cannabis Buyer’s
 Co-op, 207
 United States v. Park, 66
 United States v. Rosen, 254
 United States v. Rutherford, 98, 129–132
 United States v. Rx Depot, Inc., 176
 United States v. Shiffman, 225–226
 United States v. Sullivan, 25, 43
 United States v. Undetermined Quantities of an
 Article of Drug Labeled as Exachol, 55–64
 USV Pharmaceutical Corporation v. Weinberger, 89

V

Van Hattem v. Kmart Corporation, 480–484
 Van Iperen v. Van Bramer, 372–375
 Van Staden v. Martin, 384
 Vermont & 110th Medical Arts Pharmacy v. State
 Board of Pharmacy, 253
 Virginia State Board of Pharmacy v. Virginia Citizens
 Consumer Council, Inc., 183–185, 407–411

W

Walgreen Co. v. Selcke, 392, 417–420
 Warner-Lambert Co. v. Federal Trade
 Commission, 118
 Washington Legal Foundation v. Friedman,
 111–112, 116
 Washington Legal Foundation v. Henney,
 111–112, 116
 Watts v. Medicis Pharmaceutical Corp., 461
 Wedgewood Village Pharmacy, Inc. v. U.S., 178
 Wedgewood Village Pharmacy v. Drug
 Enforcement Administration, 216
 Weinberger v. Bentex Pharmaceuticals, Inc., 89
 Whalen v. Roe, 258, 301–304
 Winn Dixie of Montgomery, Inc. v. Colburn,
 196–199
 Wong v. Hohnstrom, 384
 Wyeth v. Levine, 94, 462

Y

Young v. Board of Pharmacy, 5

Z

Zogenix, Inc. v. Patrick, 205



PREFACE

I am very pleased that Kim Burns agreed to be my coauthor for the eighth edition of *Pharmacy Practice and the Law*. In this edition, we have continued the effort of previous editions: to provide a resource that is useful for teaching the facts of pharmacy law, providing a degree of depth to support those facts, and stimulating critical thinking about issues in the field. The *Eighth Edition* retains the format of the *Seventh Edition* while incorporating several of the relevant changes that have recently occurred in pharmacy law. Please refer to “New to the *Eighth Edition*” for a more detailed description of the changes between the previous edition and this updated *Eighth Edition*.

Some of the changes and updates are the result of suggestions from faculty who use this book as an assigned text in their pharmacy law courses. We greatly appreciate the valuable feedback from those using this book, and we hope that we continue to receive this feedback. Our thanks to Professor Rajul Patel, PharmD, PhD, for reviewing and editing the Medicare Part D section in Chapter 6. Although we acknowledge with gratitude the input from many trusted colleagues, we accept full responsibility for any omissions or deficiencies anyone might find in this *Eighth Edition*.

This text generally appeals to faculty who believe that a pharmacy law course should be much more than preparation for the board examination. The book reflects our position that a pharmacy law course should not be just about memorizing laws and regulations and learning the “rules of the game.” Rather, the course should prepare students to understand and critically analyze the law that governs both the profession and the products they distribute. Understanding requires that students know some history behind the laws, why they exist, how they affect pharmacy practice, and subsequently how to apply the law and how to analyze whether there is a better approach. Understanding pharmacy law is critical to understanding the profession. Pharmacy law reflects the history, social policy, and standards of practice that have created and shaped the profession into its current form. Our hope is that this book helps students to understand pharmacy law and, in the process, to develop an awareness and appreciation of the profession they otherwise might not have.

This book contains a great deal of information. Faculty should use their judgment as to how much they expect students to learn. Some might even wish to supplement this text with current articles or additional cases on the various legal topics. The text contains several cites to the *Federal Register*, *Code of Federal Regulations*, statutes, public laws, and websites for those wishing to delve deeper into the many topics presented.

Cases are included at the end of each chapter because they lead to challenging discussions, stimulate critical thinking, help students learn legal rules better and in greater depth, and kindle student interest. Each case starts with an overview designed to provide a brief explanation of the case and to generally cue the students as to what issues to think

about as they read the case. As much as possible, the court's own language has been retained. By doing so, students learn that law is seldom "black and white" but rather requires a considerable measure of reasoning and analysis to reach a decision. Faculty should recognize that the questions raised in the overview are designed to stimulate discussion. A specific correct answer might not always exist; rather, there could be several answers to some of the questions. The notes following each case serve to address the questions arising from the case and to clarify certain points about the case.

The structure of all eight chapters remains essentially the same as that of the previous edition except, of course, for the updates. As in the *Seventh Edition*, this edition includes study scenarios and study questions after various chapter sections. The instructor can use these to lead class discussions. Additional study scenarios and study questions can be found in the Instructor Manual.

CHAPTER BREAKDOWN

- **Chapter 1** provides an overview of law and the legal system.
- **Chapters 2 and 3** cover the federal regulation of medications, with Chapter 2 describing the basic regulatory framework of food and drug law and Chapter 3 applying that framework to pharmacy practice.
- **Chapters 4 and 5** discuss relevant provisions of the federal Controlled Substances Act (CSA). Chapter 4 provides an overview of the framework of the CSA, while Chapter 5 applies that framework more specifically to pharmacy practice.
- The main focus of **Chapter 6** is the significant influence of the federal government on the state-regulated practice of pharmacy and on business and financial issues related to the profession. From the standards established in the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) to the Medicare and Medicaid laws and the federal antitrust laws, federal requirements for drugs have a profound effect on the professionals who dispense and monitor drugs. This chapter also discusses some very important recent developments involving privacy, electronic records, and pharmacy reimbursement.
- **Chapter 7** describes some of the basic principles of state regulation of pharmacy practice, including licensure and standards setting. Chapter 7 is intended to provide only a general overview of state law issues and contains a discussion of some important recent regulatory trends occurring among the states and discussions of the similarities and differences among state pharmacy practice acts.
- Finally, **Chapter 8** provides an overview of malpractice and product liability for order processing and pharmaceutical care activities, with specific tips on liability avoidance through risk management programs. Chapter 8 is important, not just to understand legal risk but also to understand the conflicting judicial opinions of the societal expectations of pharmacists, why those expectations exist, and whether they are changing. Courts mirror societal values and sometimes provide us with both flattering and unflattering perspectives of our profession.

Because the overall structure of the text remains the same, faculty who have used this text in the past should not have to make major adjustments in the way they use this new edition.



NEW TO THE EIGHTH EDITION

There have been several legal/regulatory developments that have occurred since the publication of the *Seventh Edition* in 2012. This *Eighth Edition* includes those developments most relevant to the pharmacy profession. An additional change from the *Seventh Edition* is the inclusion of “Take-Away Points” after each major section in each chapter. A brief chapter-by-chapter description of substantive changes includes:

CHAPTER 1

Chapter 1 remains largely unchanged. The section “Distinguishing Criminal, Civil and Administrative Law” was moved and placed under the “Sources of U.S. Law” section and a Rhode Island case, *Blais v. Rhode Island Department of Health*, is now mentioned.

CHAPTER 2

In the “Historical Overview” section, new statistics for the Orphan Drug Act of 1983 and a brief description of the Drug Quality and Security Act of 2013 are added. This law is extensively discussed later in Chapter 3.

Other changes in the chapter include new or updated discussions of the following topics:

- The Food and Drug Administration organizational structure
- Regulation of e-cigarettes
- Medical foods
- Nutraceuticals and functional foods
- Health claims for foods and dietary supplements
- The Dietary Supplement and Nonprescription Drug Consumer Protection Act
- Dietary supplement product investigation by the New York Attorney General’s office
- Clarification of FDA authority over drug product recalls
- Adulteration examples in pharmacies
- Misbranding example in pharmacies regarding drug name on the label
- Unit dose labeling requirements for prescription drugs
- Proposed electronic distribution of package inserts
- Pregnancy warning requirements in labeling
- National Drug Code Number
- Prescription Drug User Fee Act’s effect on NDA review time
- FDA’s Drug Rating and Classification System
- FDA’s adverse event reporting system database

- FDA’s REMS program
- Postmarket drug safety information for patients and providers
- Exclusion payments by drug manufacturers (pay-for-delay agreements)
- Generic drug labeling controversies created by the courts
- Section 505(b)(2) NDAs
- Individual patient access to investigational drugs for serious diseases, including state “right to try” laws
- Expedited approval of drugs intended to treat serious or life-threatening illnesses
- Biologics and biosimilars
- Medical devices for general wellness, including computer software and mobile applications
- Unique device identifier requirement for devices
- Medical device expedited approval process
- Physician Payment Sunshine Act
- FDA regulation regarding the promotion of prescription drugs and devices through social media
- FDA regulatory authority over “off-label” use
- Replacement of *WLF v. Friedman* with *United States. v. Caronia* in the case studies section

CHAPTER 3

Chapter 3 changes from the previous edition include new or updated discussions of:

- Expiration or beyond-use dating, including USP and FDA guidelines
- Emergency contraception and Plan B
- Medication Guides
- Medication Guides and REMS
- The pharmacy compounding provisions under Section 503A
- The Drug Quality and Security Act of 2013, including FDA compliance and draft compliance guides
- USP compounding requirements
- Pedigrees, counterfeit drugs, and drug supply chain security
- The Drug Supply Chain Security Act of 2013
- Importation of prescription drugs for personal use
- FDA inspection authority of pharmacies

CHAPTER 4

Changes in Chapter 4 include new or updated discussions of the following items:

- State versus federal authority
- Medical and recreational use of marijuana
- Hydrocodone combination products rescheduled to a schedule II substance
- Tramadol as a schedule IV substance
- DEA reference available to identify controlled substances authority for mid-level practitioners by discipline and state
- Distributing versus dispensing (constructive delivery)
- Treatment of addicts outside of OTPs (DATA)
- The Combat Methamphetamine Epidemic Act of 2005 and the Methamphetamine Production Prevention Act of 2008
- Deletion of the *Seeley v. State of Washington* case in the “Case Studies” section

CHAPTER 5

Changes in Chapter 5 include new or updated discussions of the following items:

- DEA registration number of prescribers to include “G” as a beginning letter
- DEA electronic resource available to help verify active DEA registrations
- Recently released educational video (“Red Flags”) for pharmacists to assist in properly exercising their corresponding responsibility
- Dispensing of schedule II controlled substances
- State multiple-copy and security prescription form programs
- Partial filling of schedule III, IV, or V prescriptions
- Return of controlled substances to pharmacy for disposal, including the newly created DEA definitions of “collection” and “collector”
- Long-Term Care (LTC) Pharmacy
- Inventory requirements
- Distribution from a pharmacy to another practitioner
- Disposal or destruction of controlled substances

CHAPTER 6

Changes in Chapter 6 include new or updated discussions of the following items:

- OBRA '90 flow chart
- Recent updates and modifications to HIPAA
- Expansion of HIPAA to directly apply to business associates
- Updates to the HIPAA notice of privacy provision
- Modifications to HIPAA regarding patients' requests to access and obtain copies of PHI
- Update on the status of the accounting for disclosure rules
- Modifications to breaches of PHI
- New changes to HIPAA regarding marketing, sale of PHI, and patient authorizations
- Expanded penalties and enforcements under HIPAA
- Medicare Part D beneficiary costs
- Medicare Part D covered drugs and plan formularies
- Medicare Part D pharmacy access and “any willing provider”
- Medicare Part D fraud and abuse
- Medicare and provider status for pharmacists
- Medicaid reimbursement for multiple-source drugs
- Medicaid estimated acquisition cost and average wholesale price
- Litigation over state Medicaid cuts
- Medicare/Medicaid fraud and abuse laws
 - The False Claims Act (FCA)
 - The Anti-Kickback Statute (AKS)
- Long term care facility short-cycle dispensing
- Robinson-Patman Act and the Brand-Name Prescription Drugs litigation
- 340B drugs

CHAPTER 7

Few changes were made to Chapter 7 in the *Eighth Edition*. The discussion of licensing of pharmacists was updated. The section discussing the definition of the practice of pharmacy now reflects the term drug therapy management. The section on ancillary pharmacy personnel was updated to reflect recent NABP changes and state trends

regarding pharmacy technicians. The section on continuous quality improvement was also updated to discuss the recent advances in accreditation of outpatient pharmacies.

CHAPTER 8

Chapter 8 is essentially unchanged.



A SPECIAL ACKNOWLEDGMENT

I am indebted to David Brushwood, for his friendship and for being my coauthor for the first three editions of this book, and also to those who have used this text in their classrooms and provided valuable suggestions. RRA



REVIEWERS

Dave Helgeland, BS Pharm, MBA, EdD
Professor of Pharmacy Practice
South Dakota State University College of Pharmacy

David M. Baker, BS Pharm, MBA, JD
College of Pharmacy
Western New England University

Dean L. Arneson, PharmD, PhD
Dean
School of Pharmacy
Concordia University Wisconsin

Frederick M. Frankhauser, JD, MBA, RPh
MCPHS University

James Ruble, PharmD, JD
Skaggs Pharmacy Institute / University of Utah

Jeffery D. Evans, PharmD
Monroe School of Pharmacy
University of Louisiana

Jesse C. Vivian, RPh, JD
Wayne State University

Joseph L. Fink III, BSP Pharm, JD
Professor of Pharmacy Law and Policy
University of Kentucky College of Pharmacy

Mary K. Gurney, PhD, RPh
Midwestern University College of Pharmacy—Glendale

Michael Hegener, PharmD
James L. Winkle College of Pharmacy
University of Cincinnati

Roger N. Morris, RPh, JD
Midwestern University

Sarah L. Clement, EdS, CPhT
Program Director of Pharmacy Technology
Forsyth Technical Community College

Virgil Van Dusen, RPh, JD
College of Pharmacy
Southwestern Oklahoma State University

Whitney Jane A. Caudill
Manchester University

William R. Kirchain, PharmD, CDE
Xavier University of Louisiana